One of the things I find most frustrating about how GLP-1 medications are discussed in fitness spaces is the framing that somehow medication and serious training are at odds with each other. I do not think that reflects reality. These tools address different parts of the same challenge, and when used appropriately, they complement each other in a meaningful way.
What the Clinical Trials Were Actually Designed Around
The STEP and SURMOUNT trials that generated the weight loss results everyone references were not designed as medication-only interventions. They were conducted alongside structured lifestyle support, including dietary counseling and physical activity guidance. That context matters. The medications appear to reduce appetite-related barriers to behavior change. What the behavior change itself looks like is still up to the individual and the people supporting them.
Drs. Spencer and Karl Nadolsky built the Docs Who Lift brand on the principle that lifestyle is medicine first. Their approach across every GLP-1-related episode is not that medication replaces the work, but that the work shapes the quality of the outcome. I share that philosophy completely. The medication may make it easier to eat less. Training and nutrition determine what happens to your body composition while you are doing it.
What the Data Shows About Stopping
The May 2026 Docs Who Lift episode GLP-1 Maintenance: What Happens When You Lower Your Dose, Switch Medications, or Stop Entirely examined two recent randomized controlled trials on what happens when patients reduce or discontinue treatment. The consistent finding across the literature is that most weight that was lost returns without continued lifestyle support in place.
The STEP 1 trial extension (PMID: 35441470) showed approximately two-thirds of weight lost was regained within one year of stopping semaglutide.5 A 2025 meta-analysis of randomized trials on weight regain after GLP-1 discontinuation (PMC12535773) confirmed this as a consistent pattern across drugs and populations.9 This reflects the chronic nature of obesity as a biological condition, not a character flaw in the individual.
A note on the evidence: The specific claim that maintaining training habits while on a GLP-1 protects against weight regain after discontinuation is clinically plausible and consistent with the broader weight loss maintenance literature. However, it has not yet been directly tested in a large randomized trial specifically in GLP-1 users with body composition as a primary endpoint. That distinction is worth being honest about.
What I can say with confidence is this: the people most likely to sustain their results are the ones who used the window that medication provides to build durable habits around training and nutrition. That has always been the framework that produces long-term change, with or without medication.
Practical Notes for Active Members
The December 2025 Docs Who Lift episode on GLP-1 side effects is worth flagging for anyone who trains. It covers reactive hypoglycemia and a condition called slimmer’s paralysis, a peripheral nerve issue associated with rapid weight loss. The practical guidance on keeping weight loss rate to approximately 1 percent of body weight per week or less is consistent with standard obesity medicine clinical guidance and is something active people especially should be aware of. Losing weight too aggressively increases the risk of losing both lean mass and running into these side effects. Progress that is sustainable is progress that potentiates everything else you are trying to build.
The January 2026 and October 2025 Docs Who Lift episodes on oral GLP-1 options are also worth a listen. Oral semaglutide for weight management is now available, which genuinely changes the access picture for some patients. The dosing and absorption requirements differ from the injectable formulations, and those episodes provide a clear breakdown of what that means practically.
Blog 4: Sources
- Docs Who Lift: GLP-1 Maintenance: What Happens When You Lower Your Dose, Switch Medications, or Stop Entirely. May 25, 2026. docswholift.com
- Docs Who Lift: How Often Should You Really Lift Weights? Feat. Dr. Stuart Phillips. April 2, 2026. docswholift.com
- Docs Who Lift: Bimagrumab and Semaglutide: The BELIEVE Trial Results With Dr. Stephen Heymsfield. March 23, 2026. docswholift.com
- Docs Who Lift: Oral GLP-1 (Wegovy) Is Here: Dosing, Switching, and What to Expect. January 20, 2026. docswholift.com
- Docs Who Lift: From Injections to Pills: Breaking Down the New Oral GLP-1 Data. October 23, 2025. docswholift.com
- Docs Who Lift: GLP-1 Side Effects Deep Dive: Slimmer’s Paralysis, Bladder Spasms, and Reactive Hypoglycemia. December 5, 2025. docswholift.com
- 5. Wilding JPH et al. STEP 1 extension: weight regain after semaglutide withdrawal. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID: 35441470.
- 9. Meta-analysis: Weight Regain After Discontinuation of GLP-1 Receptor Agonists and Other Anti-obesity Drugs. PMC12535773. 2025.
